|
The Affilin® platform provides a straight forward selection process
The Affilin® libraries are created by de novo generation of a binding region on the surface of small, highly stable human proteins that can be easily produced in bacteria. Based on Ubiquitin as scaffold, complex synthetic Affilin® libraries are available for selection. Scil Proteins owns the TAT Phage Display as a proprietary selection technology and cross-licensed rights to utilize Ribosome Display from CAT/MedImmune.
Affilin® molecules are selected in vitro for specific binding of predefined targets. The selection procedure is based on the physical linkage between genotype and phenotype of billions of individual clones. An automated screening procedure enables the selection of primary Affilin® molecules within a couple of weeks. Depending on the chosen selection parameters, primary Affilin® molecules with the desired binding characteristics are obtained. If required, primary Affilin® molecules are further modified to achieve higher affinities or specificities with a Kd in the nanomolar to picomolar range.
From billions of different Affilin® proteins 100 to 200 molecules are subjected to a detailed characterization. These selected molecules are already displaying dissociation constants in the low nanomolar range with high target specificity.
The analysis includes the complete sequencing of the coding region, determination of the expression yields, detailed binding analysis (ELISA, Biacore), HPLC etc.. Temperature and pH stability as well as the determination of the biological activity via cell based assays completes the initial characterisation of the primary Affilin® proteins.
|
